This Month's Profile Group: Breast Cancer Diagnostics: Start-Ups Look To Fill Gaps In The Patient Care Continuum, features profiles of Delphinus Medical Technologies, Ibris, NovaScan and Real Time Tomography. Plus these Start-Ups Across Health Care: NewGen Therapeutics, Ozics, PlantForm and PsiOxus.
You may also be interested in...
The rates of reoperation after breast conservation therapy vary between 25 and 49%, due to the presence of tumor cells remaining in the surrounding tissue after the tumor is removed. NovaScan hopes to reduce the need for these reoperations. Its FastPath residual cancer probe is designed to identify normal, benign and malignant tissue types remaining inside the surgical cavity and in excised tissue in real time during surgery.
Although standard bone cements are commonly used to treat vertebral compression fractures, these cements are not durable enough to remedy fractured hips. But a new class of biomaterials could dramatically change the landscape. Switzerland’s Ozics AG says its injectable and load-bearing implant provides an optimal level of biomechanical performance through a minimally invasive procedure.
Patients with aggressive estrogen receptor-positive breast cancer need chemotherapy in addition to treatment with anti-estrogen therapies. The question for physicians: how to determine how aggressive a cancer is going to be? Ibris Inc. is working to provide that information with a rapid, predictive, prognostic test that can identify ER-positive breast cancer patients requiring chemotherapy.